Full Press Release Details
ADC Therapeutics Announces Pricing of
Lausanne, Switzerland - September 23, 2020 - ADC
Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization
of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced
today the pricing of an upsized public offering of 6,000,000 shares of its common shares at a price of $34.00 per share. The gross
proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by
ADC Therapeutics, are expected to be approximately $204 million. The offering is expected to close on September 28, 2020, subject
to customary closing conditions. In addition, certain existing shareholders have granted the underwriters a 30-day option to purchase
up to 900,000 additional common shares. ADC Therapeutics will not receive any proceeds from the sale of such shares by the selling
Morgan Stanley, BofA Securities and
Cowen are acting as joint book-running managers for the offering. RBC Capital Markets is acting as co-manager for the offering.
The offering is being made only by
means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, from Morgan Stanley &
Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com;
BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department,
or by email at dg.prospectus_requests@bofa.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com.
A registration statement relating
to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release
shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell
or advertise, directly or indirectly, any securities of ADC Therapeutics SA, such as the common shares, in or into Switzerland
within the meaning of the Swiss Financial Services Act ("FinSA") and these securities will not be listed or admitted
to trading on the SIX Swiss Exchange or on any other regulated trading venue (exchange or multilateral trading facility) in Switzerland.
Neither this document nor any other offering or marketing material relating to these securities, such as the common shares, constitutes
or will constitute a prospectus pursuant to the FinSA, and neither this document nor any other offering or marketing material relating
to the common shares constitutes a prospectus pursuant to the FinSA, and neither this document nor any other offering or marketing
material relating to the common shares may be publicly distributed or otherwise made publicly available in Switzerland.
About ADC Therapeutics
ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused
biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs)
for patients with hematological malignancies and solid tumors. The Company develops ADCs by applying its decades of experience
in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights
for its targets. Strategic target selection for PBD-based ADCs and substantial investment in early clinical development have enabled
ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematological and solid tumor
cancers. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to confirmatory Phase
3 clinical trials, in the USA and Europe, and numerous preclinical ADCs in development.
Loncastuximab tesirine (Lonca, formerly ADCT-402), the Company's
lead product candidate, has been evaluated in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory
diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall response rate (ORR). In September 2020, ADC Therapeutics submitted
a BLA to the US FDA for Lonca for the treatment of patients with relapsed or refractory DLBCL. Camidanlumab tesirine (Cami, formerly
ADCT-301), the Company's second lead product candidate, is being evaluated in a 100-patient pivotal Phase 2 clinical trial
for the treatment of relapsed or refractory Hodgkin lymphoma (HL) after having shown an 86.5% ORR in HL patients in a Phase 1 clinical
trial. The Company is also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.
ADC Therapeutics is based in Lausanne
(Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.
Tel.: +1 917-288-7023
Tel.: +41 (0) 43 268 3231
Tel.: +1 973-415-8838